The closing price of Galera Therapeutics Inc (NASDAQ: GRTX) was $0.15 for the day, down -3.78% from the previous closing price of $0.16. On the day, 590844 shares were traded.
Ratios:
Our analysis of GRTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.36 and its Current Ratio is at 4.36.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on August 10, 2023, Downgraded its rating to Neutral and sets its target price to $0.50 from $6 previously.
BofA Securities Downgraded its Buy to Underperform on October 19, 2021, whereas the target price for the stock was revised from $17 to $2.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 08 ’24 when Schneid Yair bought 150,000 shares for $0.17 per share. The transaction valued at 25,650 led to the insider holds 8,043,203 shares of the business.
Schneid Yair bought 175,000 shares of GRTX for $30,185 on Feb 07 ’24. The 10% Owner now owns 7,893,203 shares after completing the transaction at $0.17 per share. On Feb 06 ’24, another insider, Schneid Yair, who serves as the 10% Owner of the company, bought 25,000 shares for $0.20 each. As a result, the insider paid 5,025 and bolstered with 7,718,203 shares of the company.
Stock Price History:
Over the past 52 weeks, GRTX has reached a high of $3.59, while it has fallen to a 52-week low of $0.09.
Shares Statistics:
A total of 54.39M shares are outstanding, with a floating share count of 43.53M. Insiders hold about 19.98% of the company’s shares, while institutions hold 14.88% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by RTX Corporation analysts. The consensus estimate for the next quarter is $397.36, with high estimates of $0.74 and low estimates of $2.95.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
